Main Topics
On this page you will find the Main Topics of the 3rd Delta Cure...
Virology, Pathogenesis and Diagnosis The HDV virus: latest insights Pathogenesis of HDV: the virologist point of view Pathogenesis of HDV: the immunologist point of view Epidemiology of HDV: to be revisited? Diagnosis, staging, HCC risk and antiviral therapy Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers Diagnosis of HDV: Fibroscan and other non-invasive markers Immunology of HDV in untreated and treated patients Endpoints of HDV therapy Current and new antiviral treatments PegIFN monotherapy: efficacy and safety and clinical outcomes Bulevirtide monotherapy: efficacy and safety Bulevirtide combined with interferon: efficacy and safety Bulevirtide: clinical outcomes and survival Lonafarnib with or without peg-interferon lambda New anti-HDV drugs
Virology, Pathogenesis and Diagnosis The HDV virus: latest insights Pathogenesis of HDV: the virologist point of view Pathogenesis of HDV: the immunologist point of view Epidemiology of HDV: to be revisited? Diagnosis, staging, HCC risk and antiviral therapy Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers Diagnosis of HDV: Fibroscan and other non-invasive markers Immunology of HDV in untreated and treated patients Endpoints of HDV therapy Current and new antiviral treatments PegIFN monotherapy: efficacy and safety and clinical outcomes Bulevirtide monotherapy: efficacy and safety Bulevirtide combined with interferon: efficacy and safety Bulevirtide: clinical outcomes and survival Lonafarnib with or without peg-interferon lambda New anti-HDV drugs
Virology, Pathogenesis and Diagnosis The HDV virus: latest insights Pathogenesis of HDV: the virologist point of view Pathogenesis of HDV: the immunologist point of view Epidemiology of HDV: to be revisited? Diagnosis, staging, HCC risk and antiviral therapy Diagnosis of HDV: HDV RNA quantification and new HBV biomarkers Diagnosis of HDV: Fibroscan and other non-invasive markers Immunology of HDV in untreated and treated patients Endpoints of HDV therapy Current and new antiviral treatments PegIFN monotherapy: efficacy and safety and clinical outcomes Bulevirtide monotherapy: efficacy and safety Bulevirtide combined with interferon: efficacy and safety Bulevirtide: clinical outcomes and survival Lonafarnib with or without peg-interferon lambda New anti-HDV drugs
Virology, Pathogenesis and Diagnosis
- Virology: the latest insights
- Pathogenesis: insights from liver biopsies
- Are immune responses important in HDV infection?
- New HBV biomarkers: any role in HDV?
Diagnosis, staging, HCC risk and antiviral therapy
- HDV-RNA assays: performances and clinical challenges
- Fibroscan and other non-invasive markers
- PegIFN+NUC: predictors of response
Current and new antiviral treatments
- Bulevirtide mono and combo in clinical trials
- Bulevirtide in EU: SAVE-D study update
- Bulevirtide in France: multicenter study update
- Bulevirtide for decompensated cirrhosis
- Bulevirtide in HIV coinfected patients
- Can we stop Bulevirtide? Lessons learned from viral kinetics modelling
- What have we learned from the Lonafarnib and pegIFN lambda trials?
- New antivirals for HDV, phase II studies
- What can we learn from HBV trials for HDV cure?
